TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-05-10
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of transcatheter arterial
chemoembolization combined with anti-pd-1 antibody in patients with advanced hepatocellular
carcinoma as first line therapy.